Syna Therapeutics

Syna Therapeutics is a joint venture formed by Reig Jofre and LeanBio in 2018, focused on developing high-quality biosimilars and innovative molecules. The company, headquartered at the Barcelona Science Park, aims to address the growing global demand for biological treatments. Syna Therapeutics leverages LeanBio's biological development experience and Reig Jofre's expertise in formulation, stabilization, and pharmaceutical development of biological and injectable products. The company's primary focus is on creating biosimilars, which are complex to develop and represent a significant technological challenge in the pharmaceutical industry.

In November 2022, Syna Therapeutics signed a global licensing deal with Intas Pharmaceuticals Ltd. for its biosimilar drug LB-0702, designed to treat pathologies in the field of hematology. Under this agreement, Intas received exclusive worldwide commercialization rights for LB-0702, while Syna retained responsibility for its development and manufacturing. The company planned to begin clinical trials for LB-0702 in 2023, utilizing LeanBio's technology platforms and Reig Jofre's production expertise at its new manufacturing plant in Barcelona. This facility is equipped for producing sterile injectables and lyophilized biopharmaceutical products.

Syna Therapeutics' business model involves developing biosimilars and potentially licensing them to larger pharmaceutical companies for commercialization. The company's approach aims to make biological treatments more accessible and sustainable for national health systems, potentially creating a significant social impact in a large market.

Key customers and partnerships

Syna Therapeutics' most notable partnership is with Intas Pharmaceuticals Ltd. and its wholly-owned subsidiary, Accord healthcare. This collaboration, established in November 2022, grants Intas exclusive global rights to commercialize Syna's biosimilar LB-0702. Accord healthcare, as one of the key players in the global biosimilar market, brings extensive commercial capabilities with a sales and distribution network spanning 85 countries. This partnership positions Syna Therapeutics to potentially reach a wide range of markets and patients globally with its biosimilar products.